FIELD: pharmacy. SUBSTANCE: flavane-lignan composition is made as coprecipitate of pharmaceutically active flavane-lignan with pharmaceutically acceptable carrier-substances and wetting agents. Composition has, weight %: wetting agent, 0.1-5; water-soluble sugar or cellulose derivative, 2-80 and polyvinylpyrrolidone, 5-90. Wetting agent is taken among fatty acid sorbitan esters and polyhydroxyethylene derivatives of sorbitan esters. Silimarin or silibinin are used as pharmaceutically active flavane-lignan. Flavane-lignan composition is used for treatment and prophylaxis in hepatology. EFFECT: improved rate of release, bioavailability and absorption as compared with pure flavane-lignans. 7 cl, 3 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PREPARING THE COMPLEX OF SILIBININE WITH CYCLODEXTRIN, INCLUSION COMPLEX OF SILIBININE WITH CYCLODEXTRIN, PHARMACEUTICAL COMPOSITION SHOWING ANTIHEPATOTOXIC ACTIVITY AND A METHOD OF ITS PREPARING | 1991 |
|
RU2108109C1 |
| METHOD OF PRODUCING SILIBININE | 0 |
|
SU1456013A3 |
| SILIBILIN COMPONENT FOR TREATING HEPATITIS | 2008 |
|
RU2482844C2 |
| METHOD FOR PREPARING HYDROPHILIC COMPLEX BASED ON FLAVONOLIGNANS AND PHOSPHOLIPIDS | 2006 |
|
RU2310453C1 |
| COMPOSITION FOR THERAPY OF HEPATIC PATHOLOGIES AND ONCOLOGICAL DISEASES | 2008 |
|
RU2379046C1 |
| NEW MILK THISTLE EXTRACT, METHOD FOR PREPARING AND USING IT | 2008 |
|
RU2489161C2 |
| AGENT AND METHOD FOR TREATMENT AND PROPHYLAXIS OF ONCOLOGY DISEASES | 2005 |
|
RU2283658C1 |
| ANTITUMOR LIPOSOMAL PREPARATION WITH DIRECTED EFEFCT | 2005 |
|
RU2292898C1 |
| METHOD OF PRODUCING A POLYMER-CONTAINING SILYBIN COMPOSITION | 2019 |
|
RU2716706C1 |
| COMPOSITIONS CONTAINING SULFORAPHANE OR SULFORAPHANE PRECURSOR AND EXTRACT OR POWDER OF MILK THISTLE | 2013 |
|
RU2785683C2 |
